Pharvaris N.V. Files 6-K for Jan 5 Press Release

Ticker: PHVS · Form: 6-K · Filed: Jan 8, 2024 · CIK: 1830487

Pharvaris N.V. 6-K Filing Summary
FieldDetail
CompanyPharvaris N.V. (PHVS)
Form Type6-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-update, press-release, regulatory-filing

TL;DR

**Pharvaris just dropped a 6-K, likely for a press release, so watch for new info.**

AI Summary

Pharvaris N.V. filed a 6-K on January 8, 2024, to announce a press release issued on January 5, 2024. This filing indicates that the company is providing updated information to the market, likely related to its corporate activities or drug development, as it operates in the pharmaceutical preparations industry. For investors, this matters because press releases often contain material information that can influence stock performance, such as clinical trial updates, regulatory milestones, or financial news, which could impact the value of their shares.

Why It Matters

This filing signals that Pharvaris N.V. has new, potentially market-moving information, which could affect its stock price and investor sentiment.

Risk Assessment

Risk Level: low — This filing itself is administrative and low-risk, merely announcing a press release, but the content of the press release could be high-risk.

Analyst Insight

A smart investor would immediately seek out the attached press release (Exhibit 99.1) to understand the specific information Pharvaris N.V. is disclosing, as its content will determine the actual impact on the company and its stock.

Key Players & Entities

  • Pharvaris N.V. (company) — the registrant filing the 6-K
  • January 5, 2024 (date) — date the press release was issued
  • January 8, 2024 (date) — date the 6-K was filed

Forward-Looking Statements

  • The press release (Exhibit 99.1) will contain an update on Pharvaris N.V.'s clinical trials or drug development pipeline. (Pharvaris N.V.) — medium confidence, target: Q1 2024
  • The content of the press release will lead to a noticeable movement in Pharvaris N.V.'s stock price. (Pharvaris N.V. stock) — medium confidence, target: January 8, 2024

FAQ

What is the primary purpose of this 6-K filing by Pharvaris N.V.?

The primary purpose of this 6-K filing is to report that Pharvaris N.V. issued a press release on January 5, 2024, which is attached as Exhibit 99.1 to the filing.

When was the press release mentioned in this filing issued?

The press release mentioned in this filing was issued on January 5, 2024.

What is Pharvaris N.V.'s Commission File Number?

Pharvaris N.V.'s Commission File Number is 001-40010, as stated in the filing.

Under which SEC Act is Pharvaris N.V. filing this 6-K?

Pharvaris N.V. is filing this 6-K under the Securities Exchange Act of 1934, specifically pursuant to Rule 13A-16 or 15D-16.

What is the business address of Pharvaris N.V. as listed in the filing?

The business address of Pharvaris N.V. is Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands, as stated in the filing.

Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-08 07:00:42

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHARVARIS N.V. Date: January 8, 2024 By: /s/ Berndt Modig Name: Berndt Modig Title: Chief Executive Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated January 5, 2024. 99.2 Investor Presentation, dated January 8, 2024.

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.